Results 271 to 280 of about 499,108 (302)

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

Tyrosine kinase inhibitors

Reactions Weekly, 2020
openaire   +1 more source

Tyrosine Kinase Inhibitors

CNS Drugs, 1999
Joseph A. DeMattia, Wei Zhang, William T. Couldwell   +2 more
openaire   +1 more source

Tyrosine kinase inhibitors

Reactions Weekly
  +4 more sources

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly  

[Natural tyrosine-kinase inhibitors].

Pathologie-biologie, 1992
Changes in the degree of phosphorylation of protein tyrosine residues play a major role in the regulation of cell growth and differentiation. The biological mechanisms which control the activity of enzyme systems involved in these change (i.e. protein tyrosine-kinase [PTKs] and protein tyrosine-phosphatases) remain poorly understood.
openaire   +1 more source

Tyrosine Kinase Inhibitors

2008
openaire   +2 more sources

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly